Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.

An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.

Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.

Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer.